tbuckley/cabot-search huggingface dataset:
Flexible inhibitory control of visually evoked defensive behavior by the ventral lateral geniculate nucleus
Authors: Alex Fratzl, Alice M. Koltchev, Nicole Vissers, Yu Lin Tan, Andre Marques-Smith, A. Vanessa Stempel, Tiago Branco, Sonja B. Hofer
Journal: Neuron (2021)

Animals can choose to act upon, or to ignore, sensory stimuli, depending on circumstance and prior knowledge. This flexibility is thought to depend on neural inhibition, through suppression of inappropriate and disinhibition of appropriate actions. Here, we identified the ventral lateral geniculate nucleus (vLGN), an inhibitory prethalamic area, as a critical node for control of visually evoked defensive responses in mice. The activity of vLGN projections to the medial superior colliculus (mSC) is modulated by previous experience of threatening stimuli, tracks the perceived threat level in the environment, and is low prior to escape from a visual threat. Optogenetic stimulation of the vLGN abolishes escape responses, and suppressing its activity lowers the threshold for escape and increases risk-avoidance behavior. The vLGN most strongly affects visual threat responses, potentially via modality-specific inhibition of mSC circuits. Thus, inhibitory vLGN circuits control defensive behavior, depending on an animal's prior experience and its anticipation of danger in the environment.
1426P The utility of the prognostic index for practicing the continuum of care in advanced gastric cancer: The suitability assessment and modification of the JCOG prognostic index in real-world data
Authors: K. Shimozaki, I. Nakayama, D. Takahari, H. Osumi, D. Kamiimabeppu, T. Wakatsuki, A. Oki, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi
Journal: Annals of Oncology (2021)
615P Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
Authors: G. Gurioli, V. Conteduca, N. Brighi, E. Scarpi, U. Basso, G. Fornarini, A. Mosca, M. Nicodemo, G.L. Banna, C. Lolli, G. Schepisi, G. Ravaglia, P. Ulivi, U. De Giorgi
Journal: Annals of Oncology (2021)
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Authors: Christian Buske, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David MacDonald, Veronique Leblond, Beatrice Mahe, Charles Herbaux, Jeffrey V Matous, Constantine S Tam, Leonard T Heffner, Marzia Varettoni, M Lia Palomba, Chaim Shustik, Efstathios Kastritis, Steven P Treon, Jerry Ping, Bernhard Hauns, Israel Arango-Hisijara
Journal: Journal of Clinical Oncology (2021)

PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. METHODS Patients had confirmed symptomatic WM, either previously untreated or previously treated; patients with prior rituximab had at least a minor response to their last rituximab-based regimen. Patients were randomly assigned to once-daily ibrutinib 420 mg plus rituximab or placebo plus rituximab (n = 75 per arm). The primary end point was progression-free survival (PFS). Secondary end points included response rate, time to next treatment, hemoglobin improvement, overall survival, and safety. RESULTS With a median follow-up of 50 (range, 0.5-63) months, median (95% CI) PFS was not reached (57.7 months to not evaluable) with ibrutinib-rituximab versus 20.3 months (13.0 to 27.6) with placebo-rituximab (hazard ratio, 0.250; P &lt; .0001). PFS benefit was regardless of prior treatment status, MYD88 and CXCR4 mutation status, or key patient characteristics. Higher response rates (partial response or better) were observed with ibrutinib-rituximab (76% v 31% with placebo-rituximab; P &lt; .0001) and were sustained over time. Median time to next treatment was not reached with ibrutinib-rituximab versus 18 months with placebo-rituximab. More patients receiving ibrutinib-rituximab versus placebo-rituximab had sustained hemoglobin improvement (77% v 43%; P &lt; .0001). Median overall survival was not reached in either arm. Ibrutinib-rituximab maintained a manageable safety profile; the prevalence of grade ≥ 3 adverse events of clinical interest generally decreased over time. CONCLUSION In the final analysis of iNNOVATE with a median follow-up of 50 months, ibrutinib-rituximab showed ongoing superiority across clinical outcomes in patients with WM regardless of MYD88 or CXCR4 mutation status, prior treatment, and key patient characteristics.
Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study
Authors: A. Atti, M. Ferrari, J. Castillo-Olivares, E.J.M. Monk, R. Gopal, M. Patel, K. Hoschler, M.J. Cole, A. Semper, J. Hewson, A.D. Otter, S. Foulkes, J. Islam, M. Mirfenderesky, S. Jain, J. Murira, C. Favager, E. Nastouli, M.A. Chand, C.S. Brown, J.L. Heeney, T. Brooks, V.J. Hall, S. Hopkins, M. Zambon
Journal: Journal of Infection (2021)
981P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Authors: S. Bishnoi, R. Cosman, M. Moore, R. Eek, A. Mant, R. Zielinski, L.S. Chan, Y. Ma, Q. Zhang, T. Yau, M. Aghmesheh, A.N. Tse
Journal: Annals of Oncology (2021)
1663P Prognostic impact of baseline neutrophil-to-lymphocyte ratio (NLR) and its change during treatment for overall survival in advanced SCLC
Authors: M. Ishihara, K. Chin, H. Kazahari, R. Ochiai, T. Sakamoto, S. Tanzawa, T. Honda, Y. Ichikawa, K. Watanabe, N. Seki
Journal: Annals of Oncology (2021)
1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib
Authors: R. Descourt, M. Pérol, G. Rousseau-Bussac, D. Planchard, B. Mennecier, M. Wislez, J. Cadranel, A.B. Cortot, F. Guisier, L. Galland, P. Do, R. Schott, E. Dansin, J. Arrondeau, J.B. Auliac, C. Chouaid
Journal: Annals of Oncology (2021)
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease
Authors: Partho Sen, Sami Qadri, Panu K. Luukkonen, Oddny Ragnarsdottir, Aidan McGlinchey, Sirkku Jäntti, Anne Juuti, Johanna Arola, Jennifer J. Schlezinger, Thomas F. Webster, Matej Orešič, Hannele Yki-Järvinen, Tuulia Hyötyläinen
Journal: Journal of Hepatology (2021)

Recent experimental models and epidemiological studies suggest that specific environmental contaminants (ECs) contribute to the initiation and pathology of non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanisms linking EC exposure with NAFLD remain poorly understood and there is no data on their impact on the human liver metabolome. Herein, we hypothesized that exposure to ECs, particularly perfluorinated alkyl substances (PFAS), impacts liver metabolism, specifically bile acid metabolism.In a well-characterized human NAFLD cohort of 105 individuals, we investigated the effects of EC exposure on liver metabolism. We characterized the liver (via biopsy) and circulating metabolomes using 4 mass spectrometry-based analytical platforms, and measured PFAS and other ECs in serum. We subsequently compared these results with an exposure study in a PPARa-humanized mouse model.PFAS exposure appears associated with perturbation of key hepatic metabolic pathways previously found altered in NAFLD, particularly those related to bile acid and lipid metabolism. We identified stronger associations between the liver metabolome, chemical exposure and NAFLD-associated clinical variables (liver fat content, HOMA-IR), in females than males. Specifically, we observed PFAS-associated upregulation of bile acids, triacylglycerols and ceramides, and association between chemical exposure and dysregulated glucose metabolism in females. The murine exposure study further corroborated our findings, vis-à-vis a sex-specific association between PFAS exposure and NAFLD-associated lipid changes.Females may be more sensitive to the harmful impacts of PFAS. Lipid-related changes subsequent to PFAS exposure may be secondary to the interplay between PFAS and bile acid metabolism.There is increasing evidence that specific environmental contaminants, such as perfluorinated alkyl substances (PFAS), contribute to the progression of non-alcoholic fatty liver disease (NAFLD). However, it is poorly understood how these chemicals impact human liver metabolism. Here we show that human exposure to PFAS impacts metabolic processes associated with NAFLD, and that the effect is different in females and males.
Long-term effect of exposure to lower concentrations of air pollution on mortality among US Medicare participants and vulnerable subgroups: a doubly-robust approach
Authors: Mahdieh Danesh Yazdi, Yan Wang, Qian Di, Weeberb J Requia, Yaguang Wei, Liuhua Shi, Matthew Benjamin Sabath, Francesca Dominici, Brent Coull, John S Evans, Petros Koutrakis, Joel D Schwartz
Journal: The Lancet Planetary Health (2021)

BackgroundLong-term exposure to air pollution has been linked with an increase in risk of mortality. Whether existing US Environmental Protection Agency standards are sufficient to protect health is unclear. Our study aimed to examine the relationship between exposure to lower concentrations of air pollution and the risk of mortality.MethodsOur nationwide cohort study investigated the effect of annual average exposure to air pollutants on all-cause mortality among Medicare enrolees from the beginning of 2000 to the end of 2016. Patients entered the cohort in the month of January following enrolment and were followed up until the end of the study period in 2016 or death. We restricted our analyses to participants who had only been exposed to lower concentrations of pollutants over the study period, specifically particulate matter less than 2·5 μg/m3 in diameter (PM2·5) at a concentration of up to 12 μg/m3, nitrogen dioxide (NO2) at a concentration of up to 53 parts per billion (ppb), and summer ozone (O3) at concentrations of up to 50 ppb. We adjusted for two types of covariates, which were individual level and postal code-level variables. We used a doubly-robust additive model to estimate the change in risk. We further looked at effect-measure modification by stratification on the basis of demographic and socioeconomic characteristics.FindingsWe found an increased risk of mortality with all three pollutants. Each 1 μg/m3 increase in annual PM2·5 concentrations increased the absolute annual risk of death by 0·073% (95% CI 0·071–0·076). Each 1 ppb increase in annual NO2 concentrations increased the annual risk of death by 0·003% (0·003–0·004), and each 1 ppb increase in summer O3 concentrations increased the annual risk of death by 0·081% (0·080–0·083). This increase translated to approximately 11 540 attributable deaths (95% CI 11 087–11 992) for PM2·5, 1176 attributable deaths (998–1353) for NO2, and 15 115 attributable deaths (14 896–15 333) for O3 per year for each unit increase in pollution concentrations. The effects were higher in certain subgroups, including individuals living in areas of low socioeconomic status. Long-term exposure to permissible concentrations of air pollutants increases the risk of mortality.FundingThe US Environmental Protection Agency, National Institute of Environmental Health Services, and Health Effects Institute.
552P Reasons of screening failure during the 28-day screening period in patients identified for inclusion in phase I trials and their outcome
Authors: I. Korakis, T. Darbas, F. Mathevet, S. Clementei, L. Goubault, T. Filleron, J-P. Delord, C. Bastien, C.A. Gomez-Roca
Journal: Annals of Oncology (2021)
In Search of a Better Way to Assess the Risk of Youth Exposure to Nicotine and Tobacco Products
Authors: Ruoyan Sun, David Mendez, Kenneth E. Warner
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
COVID-19–Related School Closures and Learning Modality Changes — United States, August 1–September 17, 2021
Authors: Sharyn E. Parks, Nicole Zviedrite, Samantha E. Budzyn, Mark J. Panaggio, Emma Raible, Marc Papazian, Jake Magid, Faruque Ahmed, Amra Uzicanin, Lisa C. Barrios
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Beginning in January 2021, the U.S. government prioritized ensuring continuity of learning for all students during the COVID-19 pandemic (1). To estimate the extent of COVID-19-associated school disruptions, CDC and the Johns Hopkins University Applied Physics Laboratory used a Hidden Markov Model (HMM) (2) statistical approach to estimate the most likely actual learning modality based on patterns observed in past data, accounting for conflicting or missing information and systematic Internet searches (3) for COVID-19-related school closures. This information was used to assess how many U.S. schools were open, and in which learning modalities, during August 1-September 17, 2021. Learning modalities included 1) full in-person learning, 2) a hybrid of in-person and remote learning, and 3) full remote learning.
1730P Cancer long survivor artificial intelligence follow-up (CLARIFY): Family history of cancer and lung cancer
Authors: V. Calvo, E. Niazmand, E. Carcereny, S. Jozashoori, D. Rodriguez, R. Lopez Castro, M. Guirado, C.J. Camps, R. Bernabe Caro, A.L. Ortega Granados, B. Massuti Sureda, M.A. Cobo Dols, M.R. Garcia Campelo, E. del Barco, J. Bosch-Barrera, J.L. Gonzalez-Larriba, T. Moran, A. Collazo, M.E. Vidal, M. Provencio
Journal: Annals of Oncology (2021)
601P The prognostic role of longitudinal assessment of plasma androgen receptor (AR) copy number (CN) in metastatic castration-resistant prostate cancer (mCRPC): Analysis from a prospective biomarkers trial
Authors: N. Brighi, V. Conteduca, G. Gurioli, E. Scarpi, C. Lolli, G. Schepisi, C. Casadei, S. Bleve, P. Ulivi, U. De Giorgi
Journal: Annals of Oncology (2021)
1850P Communication patterns and cascade testing among pathogenic variant carriers
Authors: D. Aguilar, Y. Chavarri Guerra, F. Mesa-Chavez, B.F. Vaca-Cartagena, A. Becerril-Gaitan, A. Aranda-Gutierrez, M.F. Ochoa-Chavez, A. Rodriguez-Faure, S. Gonzalez-Santiesteban, H.J.J. Franco-Jimenez, D. Obregón-Leal, M. Miaja-Avila, J.N. Weitzel, C. Villarreal-Garza
Journal: Annals of Oncology (2021)
Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for <i>CRLF2-</i>rearranged Ph-like ALL
Authors: Kensuke Sasaki, Takuji Yamauchi, Yuichiro Semba, Jumpei Nogami, Hiroshi Imanaga, Tatsuya Terasaki, Fumihiko Nakao, Koshi Akahane, Takeshi Inukai, Els Verhoeyen, Koichi Akashi, Takahiro Maeda
Journal: Blood (2021)
Recurrent pulmonary tuberculosis after treatment success: a population-based retrospective study in China
Authors: Qiao-Ling Ruan, Qing-Luan Yang, Feng Sun, Wei Liu, Yao-Jie Shen, Jing Wu, Ning Jiang, Jing-Yu Zhou, Ling-Yun Shao, Wen-Hong Zhang
Journal: Clinical Microbiology and Infection (2021)
270P Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Authors: S-A. Im, J.E. Kim, K.S. Lee, Y.W. Moon, H.K. Ahn, C-Y. Ock, E-J. Roh, M. Lee, M.J. Hong, S. Song, K-H. Lee, W.S. Lee
Journal: Annals of Oncology (2021)
605P Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide
Authors: R.A. Madan, S.U. Gandhy, F. Karzai, M. Bilusic, S. McMahon, J. Strauss, J. Marte, A.J. Weisman, T.G. Perk, S.D. Yip, L. Lindenberg, E. Mena Gonzalez, B. Turkbey, W.D. Figg, P. Arlen, P. Choyke, W.L. Dahut, J. Gulley
Journal: Annals of Oncology (2021)
Singing is not associated with social complexity across species
Authors: Jan Verpooten, Marcel Eens
Journal: Behavioral and Brain Sciences (2021)

Abstract Based on their social bonding hypothesis, Savage et al. predict a relation between “musical” behaviors and social complexity across species. However, our qualitative comparative review suggests that, although learned contact calls are positively associated with complex social dynamics across species, songs are not. Yet, in contrast to songs, and arguably consistent with their functions, contact calls are not particularly music-like.
Differential regulation of mRNA fate by the human Ccr4-Not complex is driven by coding sequence composition and mRNA localization
Authors: Sarah L. Gillen, Chiara Giacomelli, Kelly Hodge, Sara Zanivan, Martin Bushell, Ania Wilczynska
Journal: Genome biology (2021)

Abstract Background Regulation of protein output at the level of translation allows for a rapid adaptation to dynamic changes to the cell’s requirements. This precise control of gene expression is achieved by complex and interlinked biochemical processes that modulate both the protein synthesis rate and stability of each individual mRNA. A major factor coordinating this regulation is the Ccr4-Not complex. Despite playing a role in most stages of the mRNA life cycle, no attempt has been made to take a global integrated view of how the Ccr4-Not complex affects gene expression. Results This study has taken a comprehensive approach to investigate post-transcriptional regulation mediated by the Ccr4-Not complex assessing steady-state mRNA levels, ribosome position, mRNA stability, and protein production transcriptome-wide. Depletion of the scaffold protein CNOT1 results in a global upregulation of mRNA stability and the preferential stabilization of mRNAs enriched for G/C-ending codons. We also uncover that mRNAs targeted to the ER for their translation have reduced translational efficiency when CNOT1 is depleted, specifically downstream of the signal sequence cleavage site. In contrast, translationally upregulated mRNAs are normally localized in p-bodies, contain disorder-promoting amino acids, and encode nuclear localized proteins. Finally, we identify ribosome pause sites that are resolved or induced by the depletion of CNOT1. Conclusions We define the key mRNA features that determine how the human Ccr4-Not complex differentially regulates mRNA fate and protein synthesis through a mechanism linked to codon composition, amino acid usage, and mRNA localization.
850P Acute lymphoblastic leukemia patients receiving prophylactic cranial irradiation by volumetric modulated ARC therapy with hippocampal sparing: Dosimetric analysis
Authors: A. Yadala, A. Mukerjhi, N. Vijayaprabhu, E. Thiravayam, S. Shivakumar, K. Azhivahgan
Journal: Annals of Oncology (2021)
Infographic. The first position statement of the Concussion in Para Sport Group
Authors: Richard Weiler, Cheri Blauwet, David Clarke, Kristine Dalton, Wayne Derman, Kristina Fagher, Vincent Gouttebarge, James Kissick, Kenneth Lee, Jan Lexell, Peter Van de Vliet, Evert Verhagen, Nick Webborn, Adam Virgile, Osman Hassan Ahmed
Journal: British Journal of Sports Medicine (2021)

BackgroundA concussion is a common injury in many sports, including para sport. Aside from a more comprehensive need for concussion education, clinicians face difficulties applying concussion assessment and management guidelines to para athletes.1 At present, there is a lack of para-sport concussion research, and prior International Concussion in Sport (CIS) consensus papers have not addressed this specific population. To rectify this issue and improve concussion management provided to para athletes, the Concussion in Para Sport (CIPS) multidisciplinary expert group was created.2MethodsThe CIPS group undertook an in-depth analysis of issues specific to the para athlete within the established key clinical domains of the current (2017) Consensus Statement on Concussion in Sport.3 The existing Sports Concussion Assessment Tool 5 (SCAT5) was evaluated as part of this process and helped identify para athlete-specific concerns. Four CIPS working groups were tasked with exploring the following key clinical areas of concussion in para sport described in the most recent consensus statement of concussion in sport2: (Less)
Intracardiac Cement Embolism
Authors: Gabe Weininger, John A Elefteriades
Journal: New England Journal of Medicine (2021)

A 56-year-old man with recent kyphoplasty presented with pleuritic chest pain. Imaging showed an intracardiac foreign body. During cardiothoracic surgery, a foreign body (shown in a video) was seen perforating the right atrium and puncturing the right lung. Intracardiac cement embolism was diagnosed.
1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial)
Authors: K. Kawaguchi, N. Masuda, S. Tanaka, H. Bando, T. Nishimura, T. Kadoya, T. Yamanaka, S. Imoto, R. Velaga, N. Tamura, T. Aruga, Y. Maeshima, M. Takada, E. Suzuki, T. Ueno, S. Ogawa, H. Haga, S. Ohno, S. Morita, M. Toi
Journal: Annals of Oncology (2021)
1662P Comprehensive analysis of the metabolic enzymes in patients with small cell lung cancer using a large-scale targeted proteomics assay
Authors: G. Toyokawa, M. Kodama, N. Haratake, Y. Yamada, H. Kittaka, T. Takenaka, K. Tanaka, M. Shimokawa, K. Yamazaki, S. Takeo, I. Okamoto, Y. Oda, K.I. Nakayama
Journal: Annals of Oncology (2021)
Distal Cap-Assisted Endoscopic Mucosal Resection (EMR-DC) For Non-lifting Colorectal Polyps – Are We Doing It Right?
Authors: Ravishankar Asokkumar, Roy Soetikno
Journal: Endoscopy (2021)

Endoscopic mucosal resection (EMR) has evolved to become the widely adopted technique for managing intermediate and large non-pedunculated colorectal neoplasia. Several methods of EMR have been described in the literature. Broadly, the techniques can be classified into those that are performed with submucosal injection and those with suction alone [1]. The critical part of EMR is to resect the affected mucosa and submucosa while avoiding injuring the muscularis propria. The simplest and easiest way to prevent entrapping the muscularis propria is to inject fluid into the submucosal layer to expand it. Adequate expansion of the submucosa allows for a safe margin for resection of the diseased mucosa. By adopting the inject-lift-and-cut technique, EMR can be performed safely in any part of the gastrointestinal tract [2].
694P Methylthioadenosine phosphorylase (MTAP) deletion is more common in sarcomatoid (srcRCC) than in clear cell renal cell carcinoma (ccRCC)
Authors: A. Necchi, P. Grivas, P.E. Spiess, J. Jacob, E. Sokol, S. Ramkissoon, E. Severson, R.S.P. Huang, D.I. Lin, D.A. Mata, B. Decker, K. Mcgregor, N.A. Danziger, J.S. Ross, G. Bratslavsky
Journal: Annals of Oncology (2021)